Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
December 2025—A new Clinical and Laboratory Standards Institute document on external laboratory transport is expected to be released early next year. “It’s the first comprehensive framework for evaluating external specimen transport systems,” says Joe Wiencek, PhD, D(ABCC), document development chair and medical director and associate professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center.
November 2025—Connecting with others is crucial for strengthening the pathology profession and improving patient care. This includes connecting with colleagues, patients, and other clinical partners to share ideas, resources, and expertise.
November 2025—Nicholas Barron, an osteopathic medical student, chose pathology after a personal health experience highlighted the field’s importance in diagnosis and healing. Izak B. Dimenstein supports the American Association of Pathologists’ Assistants’ definitions for pathologists’ assistants and grossing technicians, advocating for specialized training and certification programs to ensure quality assurance in surgical pathology.
November 2025—A study analyzed data from 6,068 individuals who received a commercial blood-based CRC screening test between May 2022 and September 2024. The study found that 49% of individuals with an abnormal result received a follow-up colonoscopy within six months, with a mean time of 66.4 days.
November 2025—A HER2-low–focused IHC scoring system was validated by nine breast pathologists using digitized images of HER2 IHC slides. The system demonstrated high performance metrics, including accuracy, sensitivity, and specificity, across two data sets, validating its effectiveness.
November 2025—A study of four laboratories’ experiences with subclassifying variants of uncertain significance (VUS) found that variants were more likely to be reclassified as benign than pathogenic. The VUS-high subclass had the highest percentage of reclassifications, but represented a smaller proportion of total VUS classifications.
November 2025
Q. Clinicians at my hospital doubt my prolactin results. They report patients with prominent pituitary adenomas who have normal prolactin results. There are other patients who have hyperprolactinemia but no adenoma or galactorrhea. In those patients, the prolactin concentrations remain elevated even after therapy. Can you clarify? Read answer.
Q. Is it necessary for a lab to report a corrected sodium level when the glucose level is really high? Studies show pseudohyponatremia can occur due to hyperglycemia. How common is this, and how do we decide which correction factor to use? Is it possible that this is easily overlooked by providers due to comorbidities in patients? Some references say there is a need to correct glucose for each 100 mg/dL increase above 400 mg/dL. Read answer.
November 2025—UpToDate, a widely used clinical decision support tool, is facing competition from OpenEvidence, an AI-powered tool that provides more accurate and context-specific answers to complex clinical cases. While UpToDate is adding its own AI capabilities, the optimal source of truth for AI-driven clinical decision support remains uncertain.
November 2025—The FDA cleared Roche’s Elecsys pTau181 test, a blood-based biomarker for Alzheimer’s disease assessment in patients 55 and older. The CAP requested an exception for physician J-1 visa holders, concerned the proposed four-year visa limit could hinder international medical graduates pursuing pathology careers. The Association for Molecular Pathology and CAP published a consensus recommendation for a simplified next-generation sequencing molecular biomarker report template.
October 2025—For my inaugural column in CAP TODAY, I’d like to begin by saying thank you. Thank you, CAP members, for the honor of allowing me to serve as your president. Thanks to my mentors, peers, and colleagues for helping me along this path. And my deepest gratitude to my wife, Jenny, and my daughter, Jasmine, for the extraordinary journey that began in China and led to my own American dream in the U.S. and to Louisiana, where I practice.
